公开(公告)号：US12222351B2

公开(公告)日：2025-02-11

申请号：US17282307

申请日：2019-10-08

Applicant: SEKISUI MEDICAL CO., LTD. ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Shigeo Takayama ,  Tetsuji Naka ,  Satoshi Serada

IPC: G01N33/545

Abstract: An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed.

公开(公告)号：US20240425614A1

公开(公告)日：2024-12-26

申请号：US18548856

申请日：2022-03-03

Applicant: Nara Medical University ,  National Institutes of Biomedical Innovation, Health and Nutrition ,  Alfresa Pharma Corporation

Inventor： Masanori Matsumoto ,  Masaki Hayakawa ,  Teruhito Yasui ,  Takeharu Minamitani

IPC: C07K16/40 ,  G01N33/573

Abstract: A preparation of an antibody or an antibody derivative that can prevent or treat acquired von Willebrand syndrome (AVWS) accompanied by a disease in need of mechanical assisted circulation. The antibody or an antibody derivative has specific binding activity against ADAMTS13, von Willebrand factor (VWF) cleaving protease, which is a causative factor of the acquired von Willebrand syndrome (AVWS) in humans, and can reduce the excessive cleavage of VWF by ADAMTS13.

公开(公告)号：US20240145091A1

公开(公告)日：2024-05-02

申请号：US18488380

申请日：2023-10-17

Applicant: National Institutes of Biomedical Innovation, Health and Nutrition ,  Kagami Inc.

Inventor： Tomonori KIMURA ,  Shihoko KIMURA ,  Yasuhiro YASUTOMI ,  Masamitsu ASAKA ,  Emiko URANO ,  Daichi UTSUMI ,  Masashi MITA

IPC: G16H50/20 ,  A61K31/198 ,  A61K31/401 ,  A61P31/12 ,  G16H20/10

CPC classification number: G16H50/20 ,  A61K31/198 ,  A61K31/401 ,  A61P31/12 ,  G16H20/10

Abstract: Provided herein is a method for modulating the amount of virus in a subject comprising administering to the subject an agent for controlling an indicator associated with a D-amino acid in the subject.

公开(公告)号：US20230159924A1

公开(公告)日：2023-05-25

申请号：US17905442

申请日：2021-03-02

Applicant: MITSUBISHI TANABE PHARMA CORPORATION ,  KYOTO UNIVERSITY ,  OSAKA UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Jun KOTERA ,  Koh ONO ,  Takahiro HORIE ,  Tomohiro YAMASAKI ,  Satoshi KOYAMA ,  Satoshi OBIKA ,  Yuya KASAHARA

IPC: C12N15/113 ,  A61P9/00

CPC classification number: C12N15/113 ,  A61P9/00 ,  C12N2310/11 ,  C12N2310/32 ,  C12N2310/3341 ,  C12N2310/315

Abstract: A prophylactic or therapeutic agent for an aneurysm comprising a miR-33b inhibiting substance, preferably an antisense oligonucleotide against miR-33b, as an active ingredient.

公开(公告)号：US11234995B2

公开(公告)日：2022-02-01

申请号：US16068163

申请日：2017-01-05

Applicant: OSAKA UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Masayuki Nakamori ,  Hideki Mochizuki ,  Satoshi Obika ,  Takanori Yokota ,  Tetuya Nagata ,  Yuya Kasahara

IPC: C12N15/11 ,  A61K31/712 ,  C07K14/47 ,  C12N15/113 ,  C07H21/02 ,  C12N15/09 ,  A61P25/28 ,  A61P25/16

Abstract: The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of α-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an α-synudein gene, has activity for inhibiting expression of the α-synudein gene, and is complementary to the α-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.

公开(公告)号：US20210382041A1

公开(公告)日：2021-12-09

申请号：US17282307

申请日：2019-10-08

Applicant: SEKISUI MEDICAL CO., LTD. ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Shigeo TAKAYAMA ,  Tetsuji NAKA ,  Satoshi SERADA

IPC: G01N33/545

Abstract: An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed.

公开(公告)号：US11058758B2

公开(公告)日：2021-07-13

申请号：US15528002

申请日：2015-03-20

Applicant: National Institutes of Biomedical Innovation, Health and Nutrition

Inventor： Ken Ishii ,  Etsushi Kuroda ,  Burcu Temizoz

IPC: A61K39/12 ,  A61K39/39 ,  A61K45/00 ,  A61K31/7088 ,  A61K31/7084 ,  A61K31/352 ,  A61K39/00

Abstract: The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.

公开(公告)号：US11053308B2

公开(公告)日：2021-07-06

申请号：US16323142

申请日：2017-08-04

Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA ,  JICHI MEDICAL UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Ayako Kakiuchi ,  Atsuhiko Kato ,  Shuji Hayashi ,  Izumi Yanagisawa ,  Ryo Konno ,  Sachiho Netsu ,  Tadashi Sankai

IPC: A61K39/395 ,  C07K16/24 ,  A61P15/00 ,  A61P29/00 ,  A61P11/00 ,  A61K45/00 ,  A61P1/16 ,  A61P13/12 ,  A61P43/00 ,  A61P17/06 ,  A61P15/08 ,  C07K16/28 ,  A61K39/00

Abstract: For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

公开(公告)号：US10889805B2

公开(公告)日：2021-01-12

申请号：US15557477

申请日：2016-03-09

Applicant: National Institutes of Biomedical Innovation, Health and Nutrition ,  Osaka University

Inventor： Hiroyuki Mizuguchi ,  Kazuo Takayama

IPC: C12N5/00 ,  C12N1/00 ,  C12N5/10 ,  G01N33/50 ,  C12N5/071 ,  C12Q1/02

Abstract: Provided is a selective method for inducing differentiation from pluripotent stem cells to enterocyte-like cells. Also provided is an excellent enterocyte-like cell expressing drug-metabolizing enzymes and drug transporters. More specifically, provided is an enterocyte-like cell having properties closer to those of primary enterocytes, which are difficult to acquire. The foregoing is achieved by adding an ALK5 inhibitor (SB431542), Wnt3a, and EGF to a culture system of definitive endoderm cells obtained by differentiation induction from pluripotent stem cells and extending a culture time. The foregoing is also achieved by introducing CDX2 gene and/or FOXA2 gene into the pluripotent stem cells or the definitive endoderm cells. The foregoing is also achieved by overlaying a basement membrane matrix on the enterocyte-like cells.

公开(公告)号：US20210003546A1

公开(公告)日：2021-01-07

申请号：US16977918

申请日：2019-03-08

Applicant: MANDOM CORPORATION ,  OSAKA UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Manami Toriyama ,  Fumitaka Fujita ,  Fumihiro Okada ,  Ken Ishii

IPC: G01N33/483 ,  G01N33/569

Abstract: Provided is a method whereby an objective indicator of an immune-related disease can be rapidly and easily detected, the method comprising detecting, as an indicator of an immune-related disease, a difference in the result of observing a primary cilium of an immune-related cell between a subject specimen and a normal specimen.